» Articles » PMID: 22207827

The "technoscientization" of Medicine and Its Limits: Technoscientific Identities, Biosocialities, and Rare Disease Patient Organizations

Overview
Journal Poiesis Prax
Specialty Medical Ethics
Date 2011 Dec 31
PMID 22207827
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The fact that the emergence of "technoscience," resulting from the coalescing of science and technology, may have serious social and cultural impact has been debated in recent years particularly with regard to the field of medicine. The present article is exploring the scope and limits of the "technoscientization" of medicine using the example of rare disease patient associations. It is investigated whether and to what extent these organizations adopt technoscientific illness identities and subscribe to the research priorities and objectives of biomedicine. In addition, it is analyzed whether Paul Rabinow's highly influential concept of biosociality entails a technoscientific model of identity or, quite to the contrary, offers a framework for contesting biomedical ascriptions of identities. As the article shows, patient associations do refer to technoscientific definitions of diseases yet constantly modify and transform them based on their everyday illness experiences. Likewise, the "biosociality" of rare disease patients emerges from the shared experience of having been neglected by mainstream medical research rather than from supposedly objective biomedical classifications.

Citing Articles

The Precision Medicine Nation.

Sabatello M, Appelbaum P Hastings Cent Rep. 2017; 47(4):19-29.

PMID: 28749054 PMC: 5568692. DOI: 10.1002/hast.736.


Understanding collective agency in bioethics.

Beier K, Jordan I, Wiesemann C, Schicktanz S Med Health Care Philos. 2016; 19(3):411-22.

PMID: 26948497 DOI: 10.1007/s11019-016-9695-4.


Exploring the positions of German and Israeli patient organizations in the bioethical context of end-of-life policies.

Raz A, Jordan I, Schicktanz S Health Care Anal. 2012; 22(2):143-59.

PMID: 22729899 DOI: 10.1007/s10728-012-0213-4.

References
1.
Sulik G . Managing biomedical uncertainty: the technoscientific illness identity. Sociol Health Illn. 2009; 31(7):1059-76. DOI: 10.1111/j.1467-9566.2009.01183.x. View

2.
Panofsky A . Generating sociability to drive science: patient advocacy organizations and genetics research. Soc Stud Sci. 2011; 41(1):31-57. DOI: 10.1177/0306312710385852. View

3.
Terry S, Terry P, Rauen K, Uitto J, Bercovitch L . Advocacy groups as research organizations: the PXE International example. Nat Rev Genet. 2007; 8(2):157-64. DOI: 10.1038/nrg1991. View

4.
Huyard C . How did uncommon disorders become 'rare diseases'? History of a boundary object. Sociol Health Illn. 2009; 31(4):463-77. DOI: 10.1111/j.1467-9566.2008.01143.x. View

5.
Huyard C . What, if anything, is specific about having a rare disorder? Patients' judgements on being ill and being rare. Health Expect. 2009; 12(4):361-70. PMC: 5060508. DOI: 10.1111/j.1369-7625.2009.00552.x. View